アラバマ州における過体重の臨床試験
アラバマ州内の拠点で、過体重に関する31件の研究が参加者を募集しています。
アラバマ州内の都市
公式研究テキスト（英語）
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Cahaba Research - Pelham /ID# 282381, Pelham
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/10/02更新 · NCT07752979AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
- Univ of Alabama Birmingham, Birmingham
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07533175A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)
- Cullman Clinical Trials, Cullman
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07823608Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
- AMR Clinical - Mobile, Mobile
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07685808Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- University of Alabama - Birmingham, Birmingham
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/28更新 · NCT07837973AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
- Pinnacle Research Group LLC, Anniston
- Univ of Alabama Birmingham, Birmingham
- Chambliss Clinical Trials LLC, Montgomery
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07720271A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- Pinnacle Research Group, LLC, Anniston
- Central Research Associates, Birmingham
- Cahaba Research - Pelham, Pelham
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07794579Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Digestive Health Specialists, Dothan
被験者募集中第3相
18歳〜70歳 · 全性別 · 2026/09/24更新 · NCT06937099Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Digestive Health Specialists, Dothan
被験者募集中第3相
18歳〜70歳 · 全性別 · 2026/09/24更新 · NCT06937086A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- Birmingham Clinical Research, Birmingham
- Cullman Clinical Trials, Cullman
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07282600A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- Birmingham Clinical Research, Birmingham
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07392190A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Fairhope
- Research Site, Huntsville
- Research Site, Mobile
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07784270A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
- Cullman Clinical Trials, Cullman
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07369011Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Alliance For Multispecialty Research - Daphne, Daphne
- Eastern Shore Research Institute, Fairhope
- Heart Center Research LLC, Huntsville
- 他2件
被験者募集中第3相
45歳〜99歳 · 全性別 · 2026/09/22更新 · NCT07037433A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- MFA Clinical Research, Tuscaloosa
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07321886Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- AMR Clinical, Mobile
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07353931A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Birmingham
- AURORA-1 Clinical Site, Huntsville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/16更新 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Birmingham
- AURORA-2 Clinical Site, Huntsville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/16更新 · NCT07743450A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Lakeview Clinical Research, Guntersville
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/14更新 · NCT07351058A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Pinnacle Research Group, Anniston
- Alabama Clinical Therapeutics, Birmingham
- University of Alabama at Birmingham, Birmingham
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/14更新 · NCT07351045A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Birmingham
被験者募集中第3相健康なボランティア歓迎
18歳〜79歳 · 全性別 · 2026/09/11更新 · NCT07654374Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
- Uni of Alabama at Birmingham, Birmingham
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/09更新 · NCT07770841Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Cullman
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/03更新 · NCT07284901Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Pinnacle Research Group LLC, Anniston
- Alliance For Multispecialty Research - Daphne, Daphne
- Alliance for Multispecialty Research Mobile, Mobile
被験者募集中第3相
18歳〜99歳 · 全性別 · 2026/09/03更新 · NCT07684235Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Anniston
- Kailera Clinical Site, Birmingham
- Kailera Clinical Site, Cullman
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/03更新 · NCT07284875Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Cahaba Research, Inc., Pelham
被験者募集中第3相
18歳〜99歳 · 全性別 · 2026/08/27更新 · NCT07575399A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Dothan
- Research Site, Huntsville
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/25更新 · NCT07784725Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Birmingham
- ACCOMPLISH-1 Research Site, Birmingham
被験者募集中第3相
18歳〜79歳 · 全性別 · 2026/08/10更新 · NCT07654361Time-restricted Eating for Postpartum Weight Loss
- University of Alabama at Birmingham, Birmingham
被験者募集中
18歳以上 · 女性 · 2026/06/29更新 · NCT06491537Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes
- University of Alabama at Birmingham, Birmingham
被験者募集中
18歳〜45歳 · 女性 · 2026/06/24更新 · NCT05124808FELLAShip to Better Health
- The Worship Center Cristian Church, Birmingham
被験者募集中
18歳以上 · 男性 · 2026/01/22更新 · NCT07220213ClinicalTrials.govより、2026/10/03時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。